Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

Recommendations for reporting post-transplant relapse in AML

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 2017; 129: 424–447.

    Article  Google Scholar 

  2. Zhou Y, Othus M, Araki D, Wood BL, Radich JP, Halpern AB et al. Pre- and post-transplant quantification of measurable (‘minimal’) residual disease via multiparameter flow cytometry in adult acute myeloid leukemia. Leukemia 2016; 30: 1456–1464.

    Article  CAS  Google Scholar 

  3. Rossi G, Carella AM, Minervini MM, di Nardo F, de Waure C, Greco MM et al. Optimal time-points for minimal residual disease monitoring change on the basis of the method used in patients with acute myeloid leukemia who underwent allogeneic stem cell transplantation: a comparison between multiparameter flow cytometry and Wilms’ tumor 1 expression. Leuk Res 2015; 39: 138–143.

    Article  Google Scholar 

  4. Kwon M, Martínez-Laperche C, Infante M, Carretero F, Balsalobre P, Serrano D et al. Evaluation of minimal residual disease by real-time quantitative PCR of Wilms’ tumor 1 expression in patients with acute myelogenous leukemia after allogeneic stem cell transplantation: correlation with flow cytometry and chimerism. Biol Blood Marrow Transplant 2012; 18: 1235–1242.

    Article  CAS  Google Scholar 

  5. Fang M, Storer B, Wood B, Gyurkocza B, Sandmaier BM, Appelbaum FR . Prognostic impact of discordant results from cytogenetics and flow cytometry in patients with acute myeloid leukemia undergoing hematopoietic cell transplantation. Cancer 2012; 118: 2411–2419.

    Article  Google Scholar 

  6. Hokland P, Cotter F . Readying the minimal residual disease concept in acute myeloid leukaemia for prime time-the American way. Br J Haematol 2013; 162: 429–430.

    Article  Google Scholar 

  7. Bassan R . Using minimal residual disease to improve treatment response definitions and hematopoietic cell transplantation strategy in acute leukemia. J Clin Oncol 2016; 34: 300–302.

    Article  Google Scholar 

  8. Harris AC, Kitko CL, Couriel DR, Braun TM, Choi SW, Magenau J et al. Extramedullary relapse of acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation: incidence, risk factors and outcomes. Haematologica 2013; 98: 179–184.

    Article  Google Scholar 

  9. Shem-Tov N, Saraceni F, Danylesko I, Shouval R, Yerushalmi R, Nagler A et al. Isolated extramedullary relapse of acute leukemia after allogeneic stem-cell transplantation; different kinetics and better prognosis than systemic relapse. Biol Blood Marrow Transplant 2017; 23: 1087–1094.

    Article  Google Scholar 

  10. Solh M, DeFor TE, Weisdorf DJ, Kaufman DS . Extramedullary relapse of acute myelogenous leukemia after allogeneic hematopoietic stem cell transplantation: better prognosis than systemic relapse. Biol Blood Marrow Transplant 2012; 18: 106–112.

    Article  Google Scholar 

  11. Bejanyan N, Weisdorf DJ, Logan BR, Wang H-L, Devine SM, de Lima M et al. Survival of patients with acute myeloid leukemia relapsing after allogeneic hematopoietic cell transplantation: A Center for International Blood and Marrow Transplant Research Study. Biol Blood Marrow Transplant 2015; 21: 454–459.

    Article  Google Scholar 

  12. Duléry R, Nibourel O, Gauthier J, Elsermans V, Behal H, Coiteux V et al. Impact of Wilms’ tumor 1 expression on outcome of patients undergoing allogeneic stem cell transplantation for AML. Bone Marrow Transplant 2017; 52: 539–543.

    Article  Google Scholar 

  13. Stahl T, Badbaran A, Kröger N, Klyuchnikov E, Zabelina T, Zeschke S et al. Minimal residual disease diagnostics in patients with acute myeloid leukemia in the post-transplant period: comparison of peripheral blood and bone marrow analysis. Leuk Lymphoma 2010; 51: 1837–1843.

    Article  CAS  Google Scholar 

  14. Bacher U, Badbaran A, Fehse B, Zabelina T, Zander AR, Kröger N . Quantitative monitoring of NPM1 mutations provides a valid minimal residual disease parameter following allogeneic stem cell transplantation. Exp Hematol 2009; 37: 135–142.

    Article  CAS  Google Scholar 

  15. Grimwade D, Jovanovic JV, Hills RK, Nugent EA, Patel Y, Flora R et al. Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy. J Clin Oncol 2009; 27: 3650–3658.

    Article  CAS  Google Scholar 

  16. Horky O, Mayer J, Kablaskova L, Razga F, Krejci M, Kissova J et al. Increasing hematopoietic microchimerism is a reliable indicator of incipient AML relapse. Int J Lab Hematol 2011; 33: 57–66.

    Article  CAS  Google Scholar 

  17. Platzbecker U, Wermke M, Radke J, Oelschlaegel U, Seltmann F, Kiani A et al. Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial. Leukemia 2012; 26: 381–389.

    Article  CAS  Google Scholar 

  18. Lee HC, Saliba RM, Rondon G, Chen J, Charafeddine Y, Medeiros LJ et al. Mixed T lymphocyte chimerism after allogeneic hematopoietic transplantation is predictive for relapse of acute myeloid leukemia and myelodysplastic syndromes. Biol Blood Marrow Transplant 2015; 21: 1948–1954.

    Article  Google Scholar 

  19. Wong E, Mason K, Collins J, Hockridge B, Boyd J, Gorelik A et al. Prognostic limitations of donor T cell chimerism after myeloablative allogeneic stem cell transplantation for acute myeloid leukemia and myelodysplastic syndromes. Biol Blood Marrow Transplant 2017; 23: 840–844.

    Article  CAS  Google Scholar 

  20. Brunstein CG, Hirsch BA, Miller JS, McGlennen RC, Verfaillie CM, McGlave PB et al. Non-leukemic autologous reconstitution after allogeneic bone marrow transplantation for Ph-positive chronic myelogenous leukemia: extended remission preceding eventual relapse. Bone Marrow Transplant 2000; 26: 1173–1177.

    Article  CAS  Google Scholar 

  21. Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK . Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel on behalf of the European LeukemiaNet. Blood 2010; 115: 453–474.

    Article  Google Scholar 

Download references

Acknowledgements

Author contributions

Study concept: AR, BMS and DJW; drafting of the manuscript: AR; critical revision of the manuscript for important intellectual content: MAL, M-EP, BMS, SD and DJW.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to A Rashidi.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rashidi, A., Linden, M., Percival, ME. et al. Recommendations for reporting post-transplant relapse in AML. Bone Marrow Transplant 53, 111–113 (2018). https://doi.org/10.1038/bmt.2017.227

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2017.227

Search

Quick links